Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HepQuant to Predict Hepatic Encephalopathy in Patients Who Receive Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Refractory Ascites - a Pilot Study

NCT04664621 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT04664621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04664621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HepQuant to Predict Hepatic Encephalopathy in Patients Who Receive Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Refractory Ascites - a Pilot Study
Lead sponsor
Northwestern University
Phase
Not applicable
Overall status
Withdrawn
Start date
February 25, 2020
Completion date
September 30, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver, hepatic encephalopathy